Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin Sells 13,135 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 13,135 shares of Tempus AI stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $45.98, for a total value of $603,947.30. Following the sale, the executive vice president now owns 154,171 shares in the company, valued at $7,088,782.58. The trade was a 7.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Tempus AI Price Performance

NASDAQ:TEM opened at $48.03 on Thursday. The business’s fifty day moving average is $55.86 and its 200 day moving average is $51.48. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI during the 3rd quarter valued at $30,000. Operose Advisors LLC purchased a new position in Tempus AI during the fourth quarter worth about $25,000. Farther Finance Advisors LLC bought a new position in Tempus AI in the 4th quarter worth about $34,000. Prestige Wealth Management Group LLC raised its holdings in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at about $49,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Needham & Company LLC lifted their price objective on shares of Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. cut shares of Tempus AI from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $50.00 to $55.00 in a report on Tuesday, February 25th. Loop Capital reduced their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. TD Cowen restated a “buy” rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Finally, William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.18.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.